MDNA Life Sciences focuses on the development of non-invasive molecular tests using their proprietary Mitomic technology platform, which utilizes mitochondrial DNA (mtDNA) as a biomarker. The deck argues that mtDNA offers significant advantages over traditional biomarkers like circulating tumor cells or cell-free DNA due to its high copy number and early detection capabilities. With a state-of-the-art 2,658 square foot facility in Newcastle upon Tyne and a key licensing agreement with Labcorp for their prostate cancer biomarker, the company is positioned for commercial scale. However, the pre…
Key takeaways
- The company utilizes mitochondrial DNA (mtDNA) as a biomarker, citing benefits such as high copy number for earlier detection and high sensitivity (Slide 8).
- MDNA operates a 2,658 square foot ISO 15189:2012 accredited clinical laboratory in Newcastle upon Tyne, UK (Slide 17).
- The Mitomic technology platform follows a four-stage process: biomarker identification, analytical validation, clinical validation, and product launch (Slide 11).
- Clinical trials for MET (endometriosis) and MPT (prostate cancer) were both planned for completion in 2023 with 1,000 participants each (Slide 14).
- A strategic licensing agreement for the Mitomic prostate cancer biomarker has already been signed with Labcorp (Slide 23).
- The product pipeline includes development for MOT (hereditary cancer syndromes) and MLT (lung cancer), though MLT is currently untested analytically or clinically (Slide 20).
- The management team features significant experience from Mitomics Inc., including the Chief Science Officer and Chief Business Officer (Slide 5).
- The deck omits a specific investment ask, valuation, or detailed financial projections within the provided slides.
Executive Summary: The Case for Mitochondrial DNA
MDNA Life Sciences is positioning itself at the forefront of the liquid biopsy market by pivoting away from traditional nuclear DNA biomarkers toward mitochondrial DNA (mtDNA). The core thesis of the presentation is that mtDNA provides a more stable, abundant, and early-warning signal for disease than existing technologies. The deck serves as a progress report on their clinical trials and a showcase of their operational readiness, highlighted by their UK-based laboratory and existing partnership with Labcorp.
Slide 1: Title and Branding
The cover slide is minimalist, featuring the MDNA Life Sciences logo and the title "Corporate Presentation." The background imagery consists of a large group of people arranged in the shape of a question mark, which likely symbolizes the diagnostic uncertainty the company aims to solve. There is no specific date or subtitle on this slide, though the source listing identifies it as a May 2023 presentation.
Slide 5: Management Team (cont.)
This slide introduces three key executives, emphasizing a strong pedigree in molecular biology and business development. Jennifer Creed , Chief Development Officer, joined in 2014 and is credited with identifying non-invasive approaches to molecular tests. Dr. Andrew Harbottle , Chief Science Officer, brings a PhD from the University of Newcastle and previous experience as CSO of Mitomics Inc. Robert Poulter , Chief Business Officer, also comes from Mitomics Inc., where he served as President and CEO. The shared history at Mitomics Inc. suggests a team that has worked together for a significant period in this specific niche of life sciences.
Slide 8: mtDNA as the Perfect Biomarker
This is a critical technical slide that compares mtDNA to other biomarker technologies. MDNA lists five biological features of mtDNA: High Copy Number, Mutation at High Frequency, Lack of Repair/Cell Death, Occurrence in "Healthy" Cells, and Disease-Specificity. The corresponding clinical benefits include "much earlier detection" and tests that are "highly sensitive / specific." In the "Comparable Biomarker Technology" table, MDNA points out disadvantages in competitors: Circulating Tumor Cells are "early in development," and Circulating Tumor DNA "may rapidly degrade in plasma." This slide establishes the company's competitive advantage in the molecular diagnostics space.
Slide 11: Product Overview – Mitomic Technology Platform
This slide illustrates the lifecycle of their proprietary platform. It is a circular flow moving from Biomarker Identification (detecting mitochondrial genome mutations) to Analytical Validation (defining assay methods), Clinical Validation (measuring performance), and finally Product Launch . The slide explicitly states the launch strategy: an IVD Service launch followed by an IVD kit launch. A central box highlights the value proposition: "Novel biomarkers to detect cancer earlier, more accurately, and less invasively than traditional methods."
Slide 14: Planned Clinical Trials
MDNA provides specific metrics for their two lead clinical programs. The MET (endometriosis) trial and the MPT (prostate cancer) trial both feature 1,000 participants with a planned completion date of 2023. The endpoint for MET is the "prediction of surgical outcome of endometriosis," while MPT focuses on the "prediction of clinically significant prostate cancer." A secondary MET study of 100 participants is listed with a completion date of "TBD" to evaluate diagnostic accuracy. This slide is vital for investors to track near-term milestones and regulatory progress.
Slide 17: Facilities
To demonstrate operational maturity, MDNA showcases their "state-of-the-art, 2,658 square foot clinical laboratory in Newcastle upon Tyne in the UK." The slide lists several certifications and capabilities: ISO 15189:2012 and ISO 13485:2016 . Technical capabilities mentioned include digital PCR, real-time PCR, and automated electrophoresis. The inclusion of photos of a modern, glass-heavy building and laboratory interior is intended to build confidence in the company's ability to handle high-volume testing and R&D in-house.
Slide 20: Growth and Business Opportunities (cont.)
This slide maps out the future pipeline beyond the lead indications. It includes MOT (hereditary cancer syndromes), a second-generation MET for disease monitoring, and MLT (lung cancer). Notably, the slide admits that MLT biomarkers are "untested analytically or clinically," providing a transparent look at the R&D stage. The final point mentions signed agreements and a plan to pursue distributors in sixty 'primary' target market countries, indicating a global scale-up strategy.
Slide 23: Investment Highlights
The final slide summarizes the investment case into five pillars: Novel Proprietary Technology , Future Product Pipeline (8 more in pipeline), State-of-the-Art Laboratory Facilities , Global Partnership Network (highlighting the Labcorp license), and Industry Tailwinds (demand for non-invasive tests). This slide serves as the closing argument, reminding investors of the commercial validation already achieved through the Labcorp deal.
What MDNA Does Well
The deck excels at technical differentiation. By dedicating an entire slide (Slide 8) to why mitochondrial DNA is superior to other liquid biopsy methods, they address the "why now" and "why this" questions effectively. The inclusion of specific participant numbers (1,000) and clear completion dates (2023) for their clinical trials provides a concrete timeline for value inflection points. Furthermore, the mention of the Labcorp partnership is a powerful piece of social proof, suggesting that a major industry player has already vetted the technology.
What is Missing from the Deck
The most glaring omission in the provided slides is a clear financial ask . There is no mention of how much capital is being raised, the valuation, or the specific use of proceeds. Additionally, the deck lacks unit economics —there is no information on the cost per test, the expected reimbursement price, or the projected margins. While the laboratory facilities are described, the commercial roadmap for the sixty target countries is vague, lacking detail on how these partnerships will be structured or the expected revenue share. Finally, a competitor landscape beyond a technical comparison would have been useful to see how MDNA stacks up against other well-funded liquid biopsy companies in terms of market share and funding.
Founder's Guide: What to Copy
Founders in the deep-tech or life sciences space should emulate MDNA's technical comparison table (Slide 8). Instead of just saying their tech is better, they list specific biological reasons and contrast them with the known weaknesses of competitors. This builds scientific credibility. Additionally, the Facilities slide (Slide 17) is a great way to show that a company is not just a "paper startup" but has the physical infrastructure and regulatory certifications (ISO) to execute. Finally, the Product Overview (Slide 11) clearly communicates a complex R&D process in a simple, four-step visual that any investor can understand, regardless of their scientific background.
Frequently asked questions
- What is the primary technological advantage claimed by MDNA?
- MDNA claims that mitochondrial DNA (mtDNA) is the 'perfect liquid biopsy biomarker.' According to slide 8, mtDNA has a high copy number which enables much earlier detection than other methods. It also persists in a detectable state and occurs in 'healthy' cells, allowing for highly quantitative results even with low sample material, unlike circulating tumor DNA which may rapidly degrade in plasma.
- What is the status of MDNA's clinical trials?
- As of the May 2023 presentation, MDNA had two major trials (MET and MPT) involving 1,000 participants each, with planned completion dates in 2023. The MET trial focuses on predicting surgical outcomes for endometriosis, while the MPT trial targets clinically significant prostate cancer. A smaller 100-participant trial for diagnostic accuracy was also listed as 'TBD' for completion (Slide 14).
- How does MDNA plan to commercialize its technology?
- The company employs a dual strategy of direct service and licensing. Slide 11 outlines a transition from IVD (In Vitro Diagnostic) service launches to IVD kit launches. Furthermore, slide 23 confirms they have already entered a licensing agreement with Labcorp for their prostate cancer biomarker and plan to pursue similar agreements in sixty 'primary' target market countries (Slide 20).
- Who are the key members of the management team?
- The team includes Jennifer Creed (Chief Development Officer), Dr. Andrew Harbottle (Chief Science Officer), and Robert Poulter (Chief Business Officer). Notably, both Harbottle and Poulter held senior leadership roles at Mitomics Inc. before joining MDNA, providing continuity in the specialized field of mitochondrial DNA research (Slide 5).
- What are the biggest risks identified in the deck?
- While not explicitly labeled as 'risks,' slide 20 notes that their lung cancer biomarker (MLT) is 'untested analytically or clinically.' Additionally, the reliance on third-party distributors and licensees for global expansion (sixty countries) introduces execution risk, and the heavy focus on 2023 completion dates for trials suggests a high-pressure milestone year for the company's valuation.
